Trials / Unknown
UnknownNCT04068974
Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer
Camrelizumab Combined With Apatinib for Recurrent Platinum-resistant Ovarian Cancer: a Phase 2 Single-arm Prospective Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is intend to improve the progression-free survial of the recurrent paltinum-resistant ovarian cancer. All the participants will receive camrelizumab combined with apatinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab (SHR-1210) | Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 \[PD-1\]). Monoclonal antibodies like SHR-1210 that can block this pathway. |
| DRUG | Apatinib | Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2. |
Timeline
- Start date
- 2019-10-28
- Primary completion
- 2021-06-30
- Completion
- 2022-06-30
- First posted
- 2019-08-28
- Last updated
- 2021-03-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04068974. Inclusion in this directory is not an endorsement.